Results regarding the a priori primary hypothesis of ADAPT, that administration of the tested NSAIDs would reduce the incidence of clinically diagnosed AD, were reported in a previous article.1 We regret any possible lack of clarity on this point. In our later article, we addressed the major secondary aim of the trial by comparing the treatment groups with respect to their longitudinal cognitive function scores.
Martin BK, Brandt J, Breitner JCS, et al. Can Treatment With Nonsteroidal Anti-inflammatory Drugs Protect From Dementia?—Reply. Arch Neurol. 2009;66(4):538–542. doi:10.1001/archneurol.2009.53
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.